Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M816Revenue (TTM) $M156Net Margin (%)-6.5Altman Z-Score5.0
Enterprise Value $M679EPS (TTM) $-0.2Operating Margin %-7.1Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.4Pre-tax Margin (%)-6.5Higher ROA y-yY
Price/Book6.210-y EBITDA Growth Rate %--Quick Ratio2.3Cash flow > EarningsY
Price/Sales5.15-y EBITDA Growth Rate %--Current Ratio2.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-4.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-8.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M44.9ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with VNDA

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

VNDA is held by these investors:



VNDA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kelly James PatrickSVP, CFO & Treasurer 2017-01-03Sell10,895$15.5117.34view
Polymeropoulos Mihael HristosPresident and CEO 2017-01-03Sell23,330$15.4817.57view
Baroldi PaoloSVP & Chief Medical Officer 2017-01-03Sell16,300$15.5117.34view
Gulino Richard L.SVP, General Counsel & Sec. 2017-01-03Sell10,900$15.5117.34view
Flynn James E 2016-09-23Sell1,120,461$16.569.9view
Flynn James E 2016-09-19Sell547,886$15.6616.22view
Polymeropoulos Mihael HristosPresident and CEO 2016-01-04Sell21,353$8.96103.13view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2016-01-04Sell9,564$8.96103.13view
Baroldi PaoloSVP & Chief Medical Officer 2016-01-04Sell12,380$8.96103.13view
Flynn James E 2015-12-16Buy11,170$8.97102.9view

Quarterly/Annual Reports about VNDA:

News about VNDA:

Articles On GuruFocus.com
Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis Sep 13 2017 
Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences Sep 11 2017 
Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference Sep 06 2017 
Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fa Jul 21 2017 
Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017 Jul 17 2017 
Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences Jun 05 2017 
Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference May 01 2017 
Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017 Apr 13 2017 
Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors Mar 31 2017 
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 

More From Other Websites
These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys? Sep 19 2017
Is It Too Late To Buy Vanda Pharmaceuticals Inc (VNDA)? Sep 14 2017
Summit Therapeutics Stock Gets Smoked After IPO Pricing Sep 14 2017
Vanda Pharma shares decline as goal of itch drug study not reached Sep 13 2017
Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis Sep 13 2017
Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences Sep 11 2017
Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference Sep 06 2017
Edited Transcript of VNDA earnings conference call or presentation 2-Aug-17 8:30pm GMT Sep 01 2017
Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA) is a Great Choice Aug 29 2017
Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR Aug 28 2017
5 Efficient Stocks to Buy for a Healthy Portfolio Aug 25 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US :... Aug 23 2017
Vanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : August 21, 2017 Aug 21 2017
Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3% Aug 16 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US :... Aug 09 2017
Vanda Pharmaceuticals preps for jet lag study results later this year Aug 04 2017
Vanda reports 2Q loss Aug 02 2017
Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results Aug 02 2017
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call Aug 02 2017
Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on... Jul 21 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}